Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide
Provided herein is a new form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide, which demonstrates higher stability relative to other forms of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide. In particular, this new form affords less dosage critical administration of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide relative to other forms. The new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide has been determined and is provided herein. This new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide can be characterized by any of a number of its properties, including, but not limited to, melting point, differential scanning calorimetry, infrared spectroscopic spectrum or portions thereof, solubility, methods and conditions under which this form is prepared, and/or precipitated from solution, and, when in crystalline form, the crystalline form can be characterized according to the diffraction pattern or portions thereof.
1. A polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide, characterized as having a melting point at about 169-175° C.
2. A polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide, characterized as being in crystalline form and having an x-ray powder diffraction peak at 2θ=11.0°, using CuK α radiation.
3. The polymorphic form of claim 2 , further characterized as having x-ray powder diffraction peaks at 2θ=20.1° and/or 22.2°, using CuK α radiation.
4. The polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide of claim 2 , further characterized as having an x-ray powder diffraction pattern substantially identical to FIG. 1( a ).
5. A polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide, characterized as having an attenuated total reflectance Fourier transform infrared spectrum at 1480-1440 cm −1 substantially identical to FIG. 2( a ).
6. The polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide of claim 5 , characterized as having an attenuated total reflectance Fourier transform infrared spectrum at 970-800 cm −1 substantially identical to FIG. 2( a ).
7. The polymorphic form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide of claim 1 , characterized as dissolving at about 75-85° C. in a solution of 10% (v/v) water in acetic acid.
8. A composition, wherein at least about 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 7%, or 10%, of the total 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide is in the polymorphic form provided in claim 1 .
9. The composition of claim 8 , wherein at least about 15%, 20%, 30%, 50%, or 70%, of the total 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide is in said polymorphic form.
10. The composition of claim 8 , wherein at least about 90%, 95%, or 99%, of the total 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide is in said polymorphic form.
11. A formulation comprising the polymorphic form of claim 1 , and a pharmaceutically acceptable carrier.
12. The formulation of claim 11 , which is formulated for oral administration.
13. The formulation of claim 11 , which is in solid form.
14. The formulation of claim 11 , which is a tablet or a capsule.
15. A method for treating a mammal having a medical, psychiatric and/or neurological condition or disorder comprising: (a) identifying a subject in need of treatment for a mammal having a medical, psychiatric and/or neurological condition; and (b) administering to the subject a pharmaceutically effective amount of the polymorphic form of claim 1 .
16. A compound comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin or a solvate or a hydrate thereof.
17. The 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin of claim 16 in substantially pure form.